Posts of Josh Ludwig

In an interview published by Medical Alley, Josh Ludwig, the Global Director of Commercial Operations at ScaleReady, discussed ScaleReady's innovative approach to revolutionizing the cell and gene therapy industry.

This interview provides valuable insights into Ludwig's vision for the future of CGT manufacturing, focusing on creating a robust and accessible platform that empowers the industry to deliver life-changing therapies to patients worldwide.

The power of collaborative partnerships is highlighted as a game-changer in driving commercialization efforts. By leveraging the expertise of multiple stakeholders, including researchers, clinicians and industry players, cell and gene therapy manufacturers can navigate complex challenges and accelerate the delivery of groundbreaking therapies to patients.

The road to scaling cell and gene therapies successfully lies in prioritizing simplicity and standardization. By addressing complexity first and then implementing automation strategically, the industry can bring life-changing treatments to more patients worldwide.

The future of cell and gene therapy manufacturing is poised for transformative advancements, driven by key themes that aim to enhance scalability, efficiency, and safety. One crucial theme is automation and process standardization.

Josh Ludwig discusses the need to redefine manufacturing to better treat more patients with various modalities around the world and meet the growing demand of the treatments during Medicine Maker panel.

Understand insights into the key trends that are redefining manufacturing processes in the rapidly evolving sector of CGT as discussed at the recent ISCT 2023 Annual Meeting.